Skin grafting is a type of medical grafting involving the transplantation of skin. The transplanted tissue is called a skin graft.
Scientists have found that the anti-inflammatory molecule, IL-10, may improve success rates of skin autografts (skin moved from one site of the body to another). This information provides a valuable drug target that may benefit burn and accident victims.
Research suggests that using steam inhalation as a remedy for a blocked nose or sinuses in children can be dangerous due to a high scalding risk associated with this therapy.
A great grandmother is the first person in Britain to have a wound healed using skin from dead donors.
Baxter International Inc. announced today the results of a phase III study evaluating the safety and efficacy of ARTISS in 75 patients.
In a scientific breakthrough, five boys who were unable to urinate due to pelvic injury were cured for up to six years after getting new lab-grown urethras or urinary tubes that connect with the bladder. This breakthrough comes from Wake Forest University researcher Anthony Atala. It was in 2006 that the team reported the first successful implantation of lab-grown urinary bladders into humans. Today six years after the operation all of the boys continue to do well, with normal or near-normal urinary flow. The boy first treated is now 16 years old and received his lab-grown urethra over six years ago.
Researchers at the Johns Hopkins School of Medicine have discovered that a natural product isolated from a traditional Chinese medicinal plant commonly known as thunder god vine, or lei gong teng, and used for hundreds of years to treat many conditions including rheumatoid arthritis works by blocking gene control machinery in the cell. The report, published as a cover story of the March issue of Nature Chemical Biology, suggests that the natural product could be a starting point for developing new anticancer drugs.
Stratatech Corp., a privately-held regenerative medicine company, today announced that it has been awarded a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute.
ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.
A pediatric urologist at UT Southwestern Medical Center has pioneered a successful surgical procedure for young girls who have absent or malformed vaginas, a condition that affects about one in 4,000 females.
Australian researchers are on the road to the discovery of a new form of artificial human skin that could be a boon to burn victims and other patients needing skin grafts. At present the available skin grafts are only 1 millimeter thick and serve only to replace the top epidermis layer.
ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.
Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that it has initiated a pivotal trial of Dermagraft® in subjects with venous leg ulcers (DEVO-Trial) to assess the product’s safety and efficacy in the promotion of healing venous leg ulcers (VLUs). Dermagraft is a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process.
PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.
The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc, applauded the federal government's decision last week to maintain the current, single reimbursement code for negative pressure wound therapy (NPWT) devices.
ULURU Inc. (NYSE Alternext: ULU) today announced that Gregory Bohn, M.D., FACS, Medical Director, Trinity Wound Care and Hyperbaric Medicine, Bettendorf, Iowa, has presented nine clinical posters at the 24th Annual "Clinical Symposium on Advances in Skin and Wound Care" being held in San Antonio, Texas.
The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew Plc, highlighted the results of a multi-center study which demonstrates that gauze-based Negative Pressure Wound Therapy (NPWT) achieves many of the common treatment goals defined for foam-based NPWT systems. These goals include a reduction in wound dimension, exudate, and improvement in granulation tissue.
Kinetic Concepts, Inc. (KCI) will sponsor a CME-accredited panel discussion, “The Role of NPWT in the Team Approach to Limb Salvage: Case Studies,” at the 3rd Annual Georgetown Diabetic Limb Salvage conference September 24-26.
ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.
Haemacure Corporation (TSX : HAE) reported today on current activities and released the financial results of its third quarter ended July 31.
To look at Matthew Houdek, you could never tell he was born with virtually no left ear.